NYSE:IQV - IQVIA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$104.88 +1.60 (+1.55 %)
(As of 06/19/2018 01:07 AM ET)
Previous Close$104.88
Today's Range$103.49 - $105.45
52-Week Range$87.10 - $110.67
Volume3.65 million shs
Average Volume1.25 million shs
Market Capitalization$21.31 billion
P/E Ratio24.06
Dividend YieldN/A
Beta0.64
IQVIA logoIQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone203-448-4600

Debt

Debt-to-Equity Ratio1.22
Current Ratio1.16
Quick Ratio1.16

Price-To-Earnings

Trailing P/E Ratio24.06
Forward P/E Ratio20.73
P/E Growth1.73

Sales & Book Value

Annual Sales$9.74 billion
Price / Sales2.22
Cash Flow$9.9224 per share
Price / Cash10.57
Book Value$40.19 per share
Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.07%
Return on Equity13.35%
Return on Assets4.75%

Miscellaneous

Employees55,000
Outstanding Shares206,310,000

IQVIA (NYSE:IQV) Frequently Asked Questions

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were IQVIA's earnings last quarter?

IQVIA (NYSE:IQV) released its earnings results on Wednesday, May, 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.27 by $0.07. The medical research company earned $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. IQVIA had a net margin of 13.07% and a return on equity of 13.35%. The firm's revenue was up 34.1% compared to the same quarter last year. View IQVIA's Earnings History.

When is IQVIA's next earnings date?

IQVIA is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IQVIA.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.IQVIA also updated its Q2 guidance to $1.17-1.24 EPS.

What price target have analysts set for IQV?

17 brokerages have issued 1-year target prices for IQVIA's stock. Their forecasts range from $93.42 to $128.00. On average, they anticipate IQVIA's stock price to reach $110.3776 in the next year. View Analyst Ratings for IQVIA.

Who are some of IQVIA's key competitors?

Who are IQVIA's key executives?

IQVIA's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
  • Mr. James H. Erlinger III, Consultant (Age 60)

Has IQVIA been receiving favorable news coverage?

News coverage about IQV stock has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IQVIA earned a media sentiment score of 0.10 on Accern's scale. They also gave news stories about the medical research company an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are IQVIA's major shareholders?

IQVIA's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.63%), Farallon Capital Management LLC (1.52%), Northern Trust Corp (0.85%), Dimensional Fund Advisors LP (0.58%), Legal & General Group Plc (0.34%) and Schwab Charles Investment Management Inc. (0.28%). Company insiders that own IQVIA stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for IQVIA.

Which major investors are selling IQVIA stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Sei Investments Co., Swiss National Bank, Guggenheim Capital LLC, The Manufacturers Life Insurance Company , Van ECK Associates Corp, Employees Retirement System of Texas and Northern Trust Corp. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for IQVIA.

Which major investors are buying IQVIA stock?

IQV stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Eagle Asset Management Inc., MD Sass Investors Services Inc., Carillon Tower Advisers Inc., Mackay Shields LLC, Farallon Capital Management LLC, Chilton Investment Co. LLC and Bloom Tree Partners LLC. View Insider Buying and Selling for IQVIA.

How do I buy shares of IQVIA?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $104.88.

How big of a company is IQVIA?

IQVIA has a market capitalization of $21.31 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. IQVIA employs 55,000 workers across the globe.

How can I contact IQVIA?

IQVIA's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]


MarketBeat Community Rating for IQVIA (IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about IQVIA and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.